indo-us-bio-tech-ltd

Home

Indo US Bio-Tech Ltd

Indo US Bio-Tech Ltd Financials

Indo US Bio-Tech Ltd Financial Statement

Indo US Bio-Tech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Sep 2024	Jun 2024	Mar 2024
Revenue	22.19	24.75	38.17
Operating Expense	17.05	21.03	32.67
Net Profit	4.36	3.17	4.21
Net Profit Margin	19.65	12.81	11.03
Earning Per Share	2.16	1.58	2.10
EBIDTA	5.05	3.71	5.49
Effective Tax Rate	-0.19	0.27	2.91

Particulars	Sep 2024
Revenue	22.19
Operating Expense	17.05
Net Profit	4.36
Net Profit Margin	19.65
Earning Per Share	2.16
EBIDTA	5.05
Effective Tax Rate	-0.19

Indo US Bio-Tech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	72.84	61.74	50.05
Operating Expenses Annual	62.04	52.37	43.13
Operating Profit Annual	11.11	9.40	7.10
Interest Annual	1.51	1.18	1.18
Depreciation	0.80	0.83	0.44
Net Profit Annual	8.25	7.24	5.24
Tax Annual	0.55	0.15	0.25

Particulars	Mar 2024
Total Revenue Annual	72.84
Operating Expenses Annual	62.04
Operating Profit Annual	11.11
Interest Annual	1.51
Depreciation	0.80
Net Profit Annual	8.25
Tax Annual	0.55

Indo US Bio-Tech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	0.19	0.05	0.13
Cash Flow from Operations	-4.58	0.53	2.91
Cash Flow from Investing	4.28	-6.67	-5.40
Cash Flow from Financing	1.22	6.29	2.41
Cash Flow at the End	1.10	0.19	0.05

Particulars	Mar 2024
Cash Flow at the Beginning	0.19
Cash Flow from Operations	-4.58
Cash Flow from Investing	4.28
Cash Flow from Financing	1.22
Cash Flow at the End	1.10

Indo US Bio-Tech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	15.27	15.24	14.25
PBIT Margin (%)	14.17	13.90	13.37
PBT Margin (%)	4.85	2.30	2.22
Net PROFIT Margin (%)	11.33	11.73	10.47
Return On Networth / Equity (%)	14.07	15.51	17.35
Return On Networth /Employed (%)	14.18	14.37	15.50
Return On Assets (%)	11.33	12.08	12.14
Total Debt / Equity (X)	0.22	0.26	0.40
Asset Turnover Ratio (%)	1	1.03	1.16

Particulars	Mar 2024
PBDIT Margin (%)	15.27
PBIT Margin (%)	14.17
PBT Margin (%)	4.85
Net PROFIT Margin (%)	11.33
Return On Networth / Equity (%)	14.07
Return On Networth /Employed (%)	14.18
Return On Assets (%)	11.33
Total Debt / Equity (X)	0.22
Asset Turnover Ratio (%)	1

Indo US Bio-Tech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	6.69	7.37	5.54
Total Current Assets Annual	73.09	59.91	47.06
Non Current Assets Annual	11.36	9.56	8.52
Total Shareholders Funds Annual	62.75	54.50	38.88
Total Assets Annual	84.46	69.47	55.57

Particulars	Mar 2024
Fixed Assets Annual	6.69
Total Current Assets Annual	73.09
Non Current Assets Annual	11.36
Total Shareholders Funds Annual	62.75
Total Assets Annual	84.46

Indo US Bio-Tech Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Dec 15, 2024, Indo US Bio-Tech Ltd has a market capitalization of 445.05 Cr. Value Research classifies it as a Small-Cap company.

Yes, Indo US Bio-Tech Ltd is debt-free with a debt-to-equity ratio of 0.23.

In FY 2023 , Indo US Bio-Tech Ltd recorded a total revenue of approximately 72.84 Cr marking a significant milestone in the company's financial performance.

Indo US Bio-Tech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 1.0% and 0.2% annually, respectively..

Indo US Bio-Tech Ltd's current PE ratio is 53.95.

Indo US Bio-Tech Ltd's ROCE averaged 12.9% from the FY ending March 2022 to 2024, with a median of 12.8%. It peaked at 13.1% in March 2024, reflecting strong capital efficiency over the period..

Indo US Bio-Tech Ltd's latest EBIT is Rs. 10.31 Cr, surpassing the average EBIT of Rs. 8.52 Cr over the 5 years..